Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MLN9708 and Dexamethasone in High Risk Smoldering Multiple Myeloma
NCT01660997Phase 2Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Jul 2012
- Primary completion
- Mar 2014
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of ixazomib in smoldering multiple myeloma (SMM), sponsored by National Cancer Institute. Planned start Jul 2012; status: withdrawn.
02
Drugs
ixazomib
03
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NCT01660997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01660997.